A novel FSHR-ALK and EML4-ALK double fusion variant in advanced lung adenocarcinoma: A case report

Anaplastic Lymphoma Kinase (ALK) gene fusions are detected in approximately 5% of lung adenocarcinomas, and data on double ALK fusions remain scarce because of their low occurrence rate. To date, there have been only a small number of case reports on double ALK fusions. In this report, we describe a novel double ALK fusion, FollicleStimulating Hormone Receptor (FSHR)-ALK and echinoderm microtubule-associated protein-like 4 (EML4)-ALK, which was observed in a patient with advanced lung adenocarcinoma who was sensitive to alectinib. Alectinib treatment was administered orally 300 mg twice daily. After a month, imaging re-examination revealed a significant decrease in tumour size and markedly relieved atelectasis. According to the Response Evaluation Criteria in Solid Tumours, the patient was considered to have a partial response to alectinib. To the best of our knowledge, this report is the first to describe this novel double ALK fusion in a patient, and these findings may provide a reference for other patients with such gene alterations.